Children Learning About Second-Hand Smoke (CLASS-III): A Cluster Randomised Controlled Trial of a School-Based Smoke-Free Intervention

/ Published in Featured, Non-Communicable Disease, Our Work
Children Learning About Second-hand Smoke (CLASS-III) is an ongoing multinational cRCT project of ARK Foundation in collaboration with the University of York, United Kingdom. The project aims to assess the effectiveness and cost-effectiveness of school-based Smoke-Free Intervention (SFI) in reducing children’s exposure to second-hand smoking (SHS) and the frequency and severity of respiratory symptoms. The

Stakeholder Workshop on the physical health of people living with severe mental illness including effect of COVID-19 pandemic and its responses in Bangladesh: What has been done so far and way forward

/ Published in News, News and Media, Non-Communicable Disease, Workshop
ARK Foundation in partnership with National Institute of Mental Health (NIMH) and with the technical support of Department of Health Science, University of York is implementing IMPACT SMI and IMPASS research study targeting people living with severe mental illness (SMI). As part of these research studies a stakeholder workshop was organized as on Monday, June

Health Economics Research Network-HERN launched in Bangladesh

/ Published in Blog, Event, Health Systems, New Work, Non-Communicable Disease
ARK Foundation Bangladesh, with the support from Centre from Health Economics, University of York, UK has launched Health Economics Research Network (HERN) in Bangladesh. A number of students complete undergraduate degrees in economics and health economics each year from different public and private universities of Bangladesh. However, they still require the practical experience of applying

A mHealth intervention (mTB-Tobacco) for smoking cessation in people with tuberculosis: a two-stage adaptive design, randomized trial (Quit 4 TB Trial)

/ Published in Non-Communicable Disease, Our Work
Quit 4 TB Trial project aims to assess in people with TB who smoke daily and check the effectiveness and cost effectiveness of mTB-Tobacco in achieving continuous abstinence for at least six months and also assess the effectiveness and cost effectiveness of mTB-Tobacco in enhancing TB treatment adherence and improving clinical outcomes. We will conduct a multi-center,